Therefore, based on these results, the use of BAY-117082 could be considered a promising strategy to counteract oral cancer progression, thanks its ability to modulate the NLRP3 inflammasome and apoptosis pathways. This evidence concerns the gene NLRP3 and lip and oral cavity carcinoma.